# OnCo record shr-a1904 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/shr-a1904/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "shr-a1904" ;
  schema:name "SHR-A1904"@en ;
  schema:description "SHR-A1904 is Hengrui's experimental antibody-drug conjugate aimed at Claudin 18.2, in a phase 3 trial against standard second-line treatment for advanced stomach cancer. Merck KGaA holds an option to license it outside China."@en ;
  schema:url <https://onco.cc/drugs/shr-a1904/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.biospace.com/merck-kgaa-darmstadt-germany-strengthens-oncology-pipeline-through-strategic-partnership-with-hengrui-for-next-generation-selective-parp1-inhibitor-and-antibody-drug-conjugate>, <https://clinicaltrials.gov/study/NCT06649292>, <https://clinicaltrials.gov/search?intr=SHR-A1904> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Antibody-drug conjugate (Claudin 18.2)" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cldn18-2/> ;
  onco:companies <https://onco.cc/companies/hengrui/>, <https://onco.cc/companies/merck-kgaa/> ;
  onco:trials <https://onco.cc/trials/nct05277168/>, <https://onco.cc/trials/nct07450976/>, <https://onco.cc/trials/nct07102901/>, <https://onco.cc/trials/nct07110571/>, <https://onco.cc/trials/nct06547736/>, <https://onco.cc/trials/nct07700719/> .